Automation Workflow for Oncology Drug Submission (e.g., OS, PFS) Evidence Compilation

Manual compilation of oncology efficacy endpoints like OS and PFS is a critical bottleneck, consuming weeks of biostatistician and medical writer time. Teams must extract Kaplan-Meier curves, hazard ratios, and p-values from SAS outputs or clinical data warehouses (e.g., Medidata Rave, Oracle Clinical), then manually format them for Clinical Study Reports and Integrated Summaries. This repetitive, error-prone process delays submissions and risks data inconsistencies that trigger regulatory questions. A custom automation workflow directly targets this operational drag, converting it into a scheduled, auditable pipeline.

Implementation integrates agents with statistical computing environments and document management systems like Veeva Vault. Orchestrators trigger data pulls upon study lock, apply predefined formatting rules, and draft narrative placeholders. The workflow includes mandatory review checkpoints for medical and statistical sign-off, ensuring scientific validity. Observability tracks data lineage from source to submission table, providing audit trails. This architecture reduces endpoint compilation effort by over 70%, accelerates submission timelines, and improves data consistency across integrated summaries for NDAs/BLAs.

This orchestration layer automates the manual, multi-week process of extracting Kaplan-Meier curves, hazard ratios, and statistical outputs from clinical data warehouses (e.g., Medidata Rave, Oracle Clinical) and formatting them for Clinical Study Reports and Integrated Summaries. The business value is a 70%+ reduction in compilation time, directly accelerating NDA/BLA timelines and freeing biostatisticians from repetitive data wrangling. Savings come from eliminating manual querying, copy-paste errors, and version misalignment across dozens of study documents.

Implementation integrates with enterprise systems via APIs and secure data tunnels, with agents built on frameworks like LangGraph for state management. Critical controls include pre-execution validation of statistical programs, automated discrepancy flagging by the consistency agent, and mandatory human review gates for all efficacy endpoints before locking. The orchestrator manages retries, logs all data lineage for audit, and updates the submission tracker, creating a repeatable, observable operating model for oncology evidence assembly.

Phase 1 establishes a foundational agent that extracts Kaplan-Meier curves and hazard ratios from a single clinical data warehouse (e.g., Medidata Rave, Oracle Clinical) and formats them into draft tables. This delivers a 40-50% reduction in manual data wrangling for a pilot study within 8-10 weeks. The architecture uses a lightweight LangGraph orchestrator with human-in-the-loop validation, proving the core extraction and formatting logic without disrupting active submission timelines.

Phase 2 expands the agent's logic to pool data across multiple studies for Integrated Summaries of Efficacy (ISE), integrating with document systems like Veeva Vault for automated CSR population. Phase 3 operationalizes the full pipeline with automated consistency checks against SDTM datasets and immutable audit trails. Each phase is governed by medical review checkpoints and exception routing to maintain submission quality, transforming a 6-8 week manual process into a days-long, repeatable operation.

Automating oncology endpoint compilation delivers major time savings but introduces regulatory risk if deployed without governance. The workflow's value—reducing a 6-8 week manual process to days—depends on embedded controls for data provenance, medical review, and change management. Implementation must connect clinical data warehouses (e.g., Medidata Rave, Oracle Clinical), statistical environments (SAS, R), and document systems (Veeva Vault) while preserving a defensible audit trail for every data transformation and narrative draft.

Phased rollout mitigates operational risk. Start with a single study's OS analysis, locking agent logic after validation by biostatistics. Introduce automated PFS compilation in phase two, followed by cross-study consistency checks. Each phase requires a control panel for monitoring agent confidence scores, exception rates, and reviewer sign-off latency. The final architecture must support rollback to manual processes for any endpoint, ensuring submission continuity is never compromised by automation failures.

This workflow automates the high-stakes, repetitive bottleneck of compiling Kaplan-Meier curves, hazard ratios, and statistical outputs from disparate clinical data warehouses (e.g., Medidata Rave, Oracle Clinical) into integrated summaries for an NDA/BLA. The operational upside comes from eliminating weeks of manual data wrangling and cross-referencing, directly accelerating submission timelines and reducing the risk of inconsistencies that trigger regulatory questions. Implementation requires orchestrating specialized agents for data extraction, statistical validation, and narrative drafting, integrated with systems like SAS, R, and Veeva Vault for document assembly.

Architecturally, the workflow is built on an orchestration layer (e.g., LangGraph) that coordinates data-fetching agents, applies business logic for endpoint selection, and routes outputs through mandatory medical and statistical review checkpoints before final formatting. Controls include validation against CDISC standards, discrepancy flagging across studies, and immutable audit trails for all data transformations. Deployment integrates with existing submission publishing tools and Regulatory Information Management (RIM) systems, ensuring the compiled evidence flows directly into the validated eCTD publishing pipeline without manual re-entry.